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Abstract
Defects in the mRNA export scaffold protein GANP, encoded by the MCM3AP gene, cause autosomal recessive early-onset
peripheral neuropathy with or without intellectual disability. We extend here the phenotypic range associated with
MCM3AP variants, by describing a severely hypotonic child and a sibling pair with a progressive encephalopathic syndrome.
In addition, our analysis of skin fibroblasts from affected individuals from seven unrelated families indicates that disease
variants result in depletion of GANP except when they alter critical residues in the Sac3 mRNA binding domain. GANP
depletion was associated with more severe phenotypes compared with the Sac3 variants. Patient fibroblasts showed
transcriptome alterations that suggested intron content-dependent regulation of gene expression. For example, all
differentially expressed intronless genes were downregulated, including ATXN7L3B, which couples mRNA export to
transcription activation by association with the TREX-2 and SAGA complexes. Our results provide insight into the molecular
basis behind genotype-phenotype correlations in MCM3AP-associated disease and suggest mechanisms by which GANP
defects might alter RNA metabolism.
Introduction
We and others have recently established that biallelic vari-
ants in minichromosome maintenance complex component
3-associated protein (MCM3AP) cause peripheral neuropathy
with or without impaired intellectual development (PNRIID,
MIM 618124) (1,2,3,4). This childhood-onset neurologic syndrome
is progressive and causes distal motor impairment and gait
difficulties, often resulting in wheelchair dependency and in
difficulties using proximal limbs. Most affected individuals
have impaired intellectual development or learning difficulties,
although some have normal cognition. Electrophysiological
testing and sural nerve biopsy are most compatible with
an axonal sensorimotor neuropathy, whereas some patients
have signs of demyelination. Additional features may include
upper motor neuron signs, cerebellar ataxia, eye movement
abnormalities, characteristic claw hands and foot deformities
and scoliosis. Moreover, the phenotypic range of MCM3AP-
associated disease was expanded by a report of patients who
developed peripheral neuropathy and multiple sclerosis-type
disease (5) and segregation of a heterozygous variant in a family
with periodic paralysis (6).
MCM3AP encodes for germinal center-associated nuclear
protein (GANP), which is a 218 kDa ubiquitously expressed
protein (7,8). GANP forms a scaffold for several interacting
proteins in the Transcription Export-2 (TREX-2) complex that
facilitates the nuclear export of a subset of mRNAs through
nuclear pore complexes (NPCs) (7,8,9,10). NPCs on the nuclear
envelope are composed of nucleoporins, which form channels
that have phenylalanine-glycine (FG) repeats in the middle,
forming a mesh-like network that mediates selective exchange
of components between the nucleus and cytoplasm. GANP is
a multi-domain protein in which the N-terminus contains a
cluster of six nucleoporin-like FG repeats. In the middle, GANP
has a Sac3 (Suppressor of actin 3) mRNA binding domain that
shows a high homology from yeast to metazoans (11,12,13). In
yeast, Sac3 interacts physically with nucleoporins to mediate
recruitment of the mRNA export machinery to the NPCs
(11,12,14). At its C-terminus, GANP has an acetyltransferase
domain that is crucial for localization to the nuclear envelope
and has been described as involved in acetylation of MCM3
during DNA replication (15,16).
The export of mRNAs is tightly coupled to their transcription
and processing, with strict quality control preventing the export
of misprocessed messengers, in particular pre-mRNAs with
unspliced introns (17). Thus, a defect in a particular step from
transcription, mRNA maturation and termination to export
is likely to have direct consequences on both upstream and
downstream steps. In human cells, two large transcription
export complexes TREX and TREX-2 link transcription to
mRNA export. They recognize mRNAs during early stages of
biogenesis and transfer the mature, spliced mRNAs to the
NXF1:NXT1 nuclear export factor, which facilitates their export
to the cytoplasm through interactions with the FG repeats
of nucleoporins. TREX is recruited to mRNAs during splicing
(18). TREX-2 is based on a GANP scaffold to which PCID2,
DSSI, ENY2 and CETN2/3 bind (10). TREX-2 is also associated
with transcription through the interaction of ENY2 and GANP
with RNA polymerase II (10). The multiprotein complexes
involved in transcription, processing and export share protein
components and modules reciprocally, allowing coordination or
modulation of these processes (19). For example, ENY2 in the
TREX-2 complex is also utilized by the histone deubiquitinase
(UBA) module of the large transcriptional co-activator SAGA
(Spt-Ada-Gcn5 acetyltransferase) complex (20,21). In Drosophila
melanogaster, TREX-2 and SAGA are proposed to co-regulate
transcription and mRNA export (22).
Subsets of mRNAs can be exported selectively, but themolec-
ular machinery involved and their regulation are unclear. In a fly
study, NXF1 was found to export most but not all mRNAs (23). On
the contrary, a deficiency in THOC5, a component of the TREX
complex, decreased the cytoplasmic expression of only a small
subset of mRNA enriched for those required for hematopoietic
development (24), whereas TREX-2, through GANP, promoted
the nuclear export of specific mRNA classes required for gene
expression itself, such as RNA processing, splicing, mRNP and
ribosome biogenesis (25). Furthermore, transcripts selectively
regulated by GANP in colon cancer cells had fewer introns than
those regulated by GANP and NXF1 together or NXF1 only,
suggesting that GANP may facilitate rapid changes in gene
expression by regulating the export of genes that require less
processing (9).
We have previously suggested a genotype–phenotype
correlation for pathogenic variants in MCM3AP whereby
patients with missense variants in Sac3 domain present with
milder motor phenotypes compared with patients who have
compound heterozygous variants affecting other parts of the
protein (26). To investigate the molecular consequences of the
different mutation types on GANP localization and function,
we have studied here skin fibroblasts from multiple patients
with MCM3AP-associated disease. We found that more severe
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phenotypes were characterized by near complete loss of GANP
at the nuclear envelope, whereas missense variants in the Sac3
domain of GANP did not lead to GANP depletion. Furthermore,
GANP defects impacted the overall mRNA expression in patient
fibroblasts, with differentially expressed genes showing intron
content dependency. Overall, the present study suggests that
GANP deficiency impairs transcription and/or export of specific
mRNAs, which provides novel insight into the roles of GANP in
human disease.
Results
Novel MCM3AP variants and the associated phenotypes
We identified two new families, one in the Netherlands and
one in Estonia, with variants in MCM3AP, by genome or exome
sequencing. Clinical features of these and previously reported
patients with autosomal recessive disease are listed in Supple-
mentary material Table S1.
The affected individual in Dutch family (NL2) is a girl with
severe hypotonia and intellectual disability. The patient is now
4 years 9 months old, born as the first child of healthy, non-
consanguineous parents (father Dutch, mother Thai). From the
age of 3 months, there were concerns about motor development,
as she had poor head control. She was referred to a pediatric
neurologist at the age of 7 months. Neurologic examination
showed no signs of motor and sensory neuropathy, and her neu-
rological features rather suggested a central defect. At the age
of 16 months, she was referred to a clinical geneticist because
of motor delay, hypotonia, swallowing problems and abnormal
(dyskinetic) movements. She was not dysmorphic.
At the age of 2 years 2 months, she had slow motor pro-
gression and spoke some words. Her best motor milestone was
rolling at the age of 2 years. Attempts to crawl were hampered
by a cast for severe scoliosis that she had developed. At the
age of 3 years 5 months, she spoke only six words. At the age
of 4 years 8 months—after a period of viral infections—she
started to regress. She could no longer move her legs against
gravity. She became short of breath when lying on her back. She
had recurrent upper airway infections and progressive severe
scoliosis. At the age of 4 years, she required placement of a
gastrostomy tube because of poor weight gain and vomiting.
During a period of high fever, her respiratory capacity dropped
and shewas placed on ventilatory support,which is still required
at age 4 years 9 months.
A brain MRI at the age of 10 months was normal. At the age
of 4 years 9 months, hyperintensity of the basal ganglia and
mild ventriculomegaly were seen. The radiologic finding was
suggestive of a metabolic abnormality.
An EMG at the age of 4 years 9months showed affectedmotor
and sensory fibers, with severe polyneuropathy.
Array analysis showed three copy number variants, paternal
duplication of 4p and deletion of 5q, and maternal deletion
of 7q. Whole exome analysis identified a maternally inherited
intronic variant c.4290+3G>T in MCM3AP, predicted to affect
the splicing of exon 20, and a paternally inherited frameshift
variant c.3476_3477del (p.Gln1159Argfs∗8), predicted to lead to a
premature termination (Fig. 1A). Neither variant is found in the
ExAC variant database.
The Estonian family (EST) has two affected siblings. Both are
in their late twenties (brother, EST1; sister, EST2). Theywere born
at full term to non-consanguineous Estonian parents following
an unremarkable pregnancy. Their birth weights were relatively
small (−1.75SD), but the length was 0SD and the head circum-
ferences were not known. Mild psychomotor developmental
delay was noticed in the first year of life (head control at age
5 months; standing independently at the age of 12 months).
Both siblings had severe generalized epilepsy and mild spastic
diplegia, diagnosed at the age of 3.5 years (EST1) and 8 years
(EST2). They both began to learn at a conventional school with
a conventional learning program. However, already at the age of
11 years (EST2) and 12 years (EST1), progressive encephalopathy
was diagnosed in addition to polyneuropathy, and soon drug
resistant epilepsy presented. The EEG showed slow background
activity accompanied by frequent epileptiform activity. At this
age, the head circumference, weight and length were normal.
Over the years, the symptoms constantly progressed: most of
the learned skills disappeared; both patients developed muscle
atrophy, spasticity and joint contraction; ataxia and dysarthria;
aggression and behavioral problems (mostly EST1). At the age
of 26–27 years, both individuals are mostly bedridden. They can
sit but not stand or walk. They have moderate to severe intel-
lectual disability and drug-resistant epilepsy (1–10 seizures per
day).
The EST siblings have the heterozygous c.3814G>A (p.Val1272
Met) missense variant, which we previously reported in a
Finnish family (2), and a maternally inherited novel frameshift
variant c.5423delG (p.Gly1808Aspfs∗5) (Fig. 1A). Comparison of
the sequencing data of the previously reported Finnish patients
and the Estonian patients suggested that affected individuals
from these families have the same haplotype on the c.3814G>A
(p.Val1272Met) allele as each patient also shared two rare
intronic variants in the gene (hg19: 21-47 662706 T>C and 21-
47690191G>A). These variants as well as the disease variant
(21-47676821C>T) are enriched in the Finnish population, each
having an allele frequency of about 0.0025 according to gnomAD
database.
We previously found a decrease in mRNA levels of MCM3AP
in patient fibroblasts (2). We now assessed MCM3AP mRNA
levels in the skin fibroblasts of the NL2, EST1 and EST2 patients
by quantitative PCR (qPCR), normalized to Glyceraldehyde
3-phosphate dehydrogenase (GAPDH). All three patients had
approximately 30% ofMCM3APmRNA remaining in comparison
with the expression level in healthy control fibroblasts (Fig. 1B).
As all patients carried frameshift variants on one allele, which
are expected to result in mRNA degradation, the qPCR result
suggested that the second variant in each case also affected
mRNA stability.
GANP missense variants in Sac3 domain are clustered
and probably impair interaction with RNA
Disease associatedMCM3AP variants can be roughly divided into
two classes: missense variants in the Sac3 domain of GANP and
compound heterozygous variants outside Sac3 (Supplementary
material, Table S1). Homozygous missense variants in Sac3 have
been described in several patients: p.Met762Thr in a Turkish
family (2), p.Ser951Pro in an Iranian family (4) (IR cell line in
this study), p.Arg878His in a Kurdish family (4), p.Glu915Lys in
a Dutch family (1) and p.Leu870Ser in a Lebanese family (3).
In addition, the Sac3 variant p.Ala867Asp has been found in
combination with a nonsense variant p.Tyr899∗ in an Australian
family (AUS cell line in this study) (2) (Fig. 1C). Furthermore,
peripheral neuropathy and multiple sclerosis were associated
with homozygous p.Ile954Thr variant (5). Amino acid conser-
vation of the recessive Sac3 missense variants is shown in
Supplementary material, Figure S3. To investigate in silico the
location of these missense variants in the structure of the Sac3
domain, we exploited the high level of conservation between
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Figure 1. Novel variants in MCM3AP and structural modeling of Sac3 domain variants.
(A) Family pedigrees of EST and NL2. (B) qPCR quantification ofMCM3APmRNA levels in EST1, EST2 and NL2 patient and four control fibroblasts normalized to GAPDH.
The mean of three technical replicates is shown for each cell line as dots. Bars show mean of control or patient cells. Error bars indicate SD. ∗∗ P<0.0001. (C) Map of
GANP variants investigated in this study. Variants in new families are shown in black and previously reported variants in grey. (D) Modelling of mutations in the Sac3
domain. The secondary structure of the GANP, PCID2 and DCCI chains is shown using different colors to identify specific components. The winged-helix regions of
GANP and PCID2 are shown as yellow and red, respectively, their TPR (tetratricopeptide repeats) regions in green and magenta, respectively, and DCCI as light blue. All
of the disease-associated missense variants (black) are located either in the GANP winged-helix domain (shown as yellow secondary structure) or in the GANP TPR
region (shown as green) immediately adjacent to the winged helix domain. The residues mutated are primarily located in the interior of the structure and so are likely
to generate local perturbations in the molecular conformation in this region. Although Ser951 is located on the surface, it lies within a helix, and because it is mutated
to Pro, a residue that is incompatible with an α-helix, this mutation would also probably generate a local structural perturbation. It is likely that the local structural
perturbations introduced by these mutations could influence the binding of RNAs to the GANP:PCID2:DCCI complex, either directly by changing the conformation of
the GANP winged helix domain or indirectly by altering the interaction between GANP and PCID2.
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the human GANP:PCID2:DCCI complex and the Saccharomyces
cerevisiae Sac3:Thp1:Sem1 complex for which a crystal structure
is available (27,28). The structures of both PCID2/Thp1 and GAN-
P/Sac3 in this region have a PCI fold (29) based on a series of
helical tetratricopeptide repeats (TPR) capped by a winged helix
domain (Fig. 1D, Supplementary material, Movie S1). All but one
of the Sac3 domain variants observed in the GANP patients are
clustered in a region that lies in thewinged helix domain close to
its junction with the TPR region, whereas the remaining variant
is in the TPR region immediately adjacent to the winged helix
domain. Moreover, these variants are primarily in the interior of
the protein and so probably generate local changes in structure.
This winged helix region of Sac3, together with the adjacent
PCID2, is associated with binding to RNA (28) and so local struc-
tural changes introduced by these variants would be expected to
impair RNA binding either directly or indirectly by impairing the
binding of PCID2.
Compound heterozygous MCM3AP variants outside the
Sac3 domain lead to decreased GANP in nuclear
envelope
To assess the consequences of MCM3AP variants on GANP pro-
tein, we studied skin fibroblasts from nine affected individuals
from families FIN,AUS,USA,NL1,NL2, EST, IR and the unaffected
mothers of NL1 (NLM) and IR (IRM) (Fig. 1C, Table 1). All other
patients carried compound heterozygous variants outside the
Sac3 domain, except the AUS patient, who had a heterozygous
Sac3 missense variant together with a nonsense variant, and
the IR patient, who carried the homozygous S951P variant in
the Sac3 domain (Fig. 1C). We used a polyclonal antibody that
recognizes the N-terminal region of GANP to perform immunos-
taining on these fibroblasts (Fig. 2A–C). Staining was done on
three different occasions, upon receipt of the different patient
cell lines (Fig. 2A–C). In summary, cells from affected individu-
als from families FIN, NL1, USA, EST and NL2 showed greatly
reduced GANP staining at both the nuclear envelope and the
nuclear interior when compared with control fibroblast lines
(Fig. 2A and B). In contrast to all other patient lines, the AUS and
IR cell lines carrying Sac3missense variants had a GANP staining
comparable with that of the controls (Fig. 2A and C). We quan-
tified the GANP signal by manually counting the stained cells
and grouping them depending on the intensity of staining at
the nuclear envelope. GANP+ denoted a clear presence of GANP,
GANP- denoted absence of GANP, and intermediate cells had
faint GANP staining at the nuclear envelope (Fig. 2D). The quan-
tification showed the highest number of GANP+ cells in controls
(from 61% to 100%) and AUS (91%), as well as IR/IRM (from
95% to 100%) consistent with the visual observation (Fig. 2E).
Unaffected heterozygous carrier NLM had mostly GANP+ cells
(64%). Fibroblast lines of FIN, NL1, NL2 and EST had about 1% of
GANP+ cells, whereas USA fibroblasts had none (0%). The ratio
of GANP staining in counted cells was significantly different
in all patients with variants outside the Sac3 domain (FIN1/2,
EST1/2, NL1, NL2, USA) in comparison with controls (P<0.001
for each patient), whereas patients with Sac3 variants did not
differ from controls. Staining results of controls in the last two
experiments are shown in Supplementary material, Figure S1.
Western blot analysis of GANP, which was performed in some
fibroblast lines,was consistent with the immunostaining results
(Supplementary material, Fig. S2).
In conclusion, these results showed that compound het-
erozygous MCM3AP variants outside the Sac3 domain resulted
in a decreased GANP level at the nuclear envelope. In con-
trast, patients with Sac3 domain variants had normal GANP
expression and localization.
Nuclear envelope ultrastructure in the absence of GANP
is normal
Weused three fibroblast lines from affected (FIN1, FIN2 andAUS)
and two from healthy individuals for ultrastructural assessment
by transmission electron microscopy (TEM) (Fig. 3). The appear-
ance of the nuclear envelope, nuclear pores and nucleoli and the
general appearance of cells were normal in the GANP-depleted
fibroblasts (FIN1/2) and in AUS cells carrying the Sac3 missense
variant.
Affected individuals share a transcriptome signature in
fibroblasts
Next, we assessed whether disease-associated GANP defects
influenced gene expression in fibroblasts.mRNA from fibroblast
lines FIN1/2, AUS, USA, NL1, NLM and two unrelated controls
(one male and one female) were deep sequenced using paired-
end sequencing using two technical replicates. We compared
the overall gene expression profiles by hierarchical correlation
analysis (Fig. 4A). To test if any gene expression alteration cor-
related with GANP deficiency, we performed differential gene
expression (DE) analysis using DESeq2 (30) comparing patients
with healthy controls. This analysis identified 51 downregulated
and 110 upregulated genes (compared with control fibroblasts,
FDR<0.01) (Fig. 4B). MCM3AP mRNA levels were significantly
reduced (log2FC=−0.81, FDR=1.32−06), as expected based on
qPCR results.
To identify potential pathways affected by GANP deficiency,
we used REACTOME, KEGG, DO and GO enrichment analysis
(Fig. 4D). Although this study was done using patient fibrob-
lasts, which are not the affected cell type in these patients,
DO gene sets identified pathways related to brain developmen-
tal disorders and epilepsy, and REACTOME identified pathways
related to neuronal processes. In particular, altered genes were
related to neuronal adhesion (NRXN3), protein–protein inter-
actions at synapses (SLITRK1, NLGN1 and APBA2), potassium
channels (KCNA7, KCNMA1 and KCNQ5) and other neuronal and
synaptic processes (RIMS1, GRIA1, GABRB3, PTPRD and CACNB4)
(Fig. 4C).
GANP has been previously suggested to be selectively
involved in the export of highly expressed and rapidly regulated
genes, which tend to be shorter and have fewer introns than
genes in general (9). Therefore, we examined the number of
introns in the identified DE genes. Interestingly, we noticed that
the distribution of exons was significantly different between up-
and downregulated genes (Fig. 5A), by Wilcoxon rank sum test
with continuity correction (Mann–Whitney U test W =1772.5,
P-value < 0.0002). For example, of the 51 downregulated DE
genes, 15 were intronless, whereas all upregulated genes had
introns (Fig. 5B). We validated the downregulation of three
intronless genes ATXN7L3B (P<0.0001), TSPYL4 (P<0.0001) and
EID1 (<0.0001) by qPCR, including eight patient lines in the
analysis in comparison with control cells (Fig. 5C).
Taken together, these results suggest that GANP defects
in patient fibroblasts affect the expression of a limited
number of genes, and that intron content is a contributing
factor.
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Figure 2. Variants outside Sac3 domain cause loss of GANP protein.
Immunocytochemistry with an N-terminal GANP antibody in patient fibroblasts. (A) Confocal images of patient group A (AUS, FIN1, FIN2, USA and NL1) and control
fibroblasts stained with GANP antibody show normal localization to the nuclear envelope and interior in control and AUS cells and reduction in staining in other
affected individuals’ cell lines. NLM refers to cell line of mother of NL1. (B) Confocal images of patient group B (EST1, EST2 and NL2). (C) Confocal images of patient
group C (IR). IRM refers to cell line of mother of IR. (D) Example of categorization of cells into GANP +, GANP intermediate or GANP –. (E) Bar graph shows quantification
of GANP protein levels relative to GAPDH for A-C. Bar graph quantification of GANP staining in the nucleus and the nuclear envelope as fraction of cells from blindly
counted cells for that sample. Cells were classified into GANP + (black), intermediate (−/+) (dark grey) and GANP—(light grey) cells based on staining in the nuclear
envelope and interior.Quantification is based on technical triplicate samples of the same experiment naverage = 112 for samples A and technical duplicates naverage = 136
for samples B, naverage = 90 for duplicate samples in experiment C. Dapi stains nuclei. Scale bars: 10 μm. See Supplementary material figure S1A for control samples
for experiments B and C.
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Table 1. Human fibroblast lines used in this study
Affected individual designation
(current study)
Affected individual designation
(original study)
MCM3AP variants Reference
FIN1 F:II-3 p.V1272M and p.P148Lfs∗48 (2)
FIN2 F:II-4 p.V1272M and p.P148Lfs∗48 (2)
AUS A:II-2 p.A867D and p.Y889∗ (2)
NL1 N:II-1 p.Q619=and p.N1317fs∗18 (2)
NLM N:I-2 Heterozygous p.N1317fs∗18 (2)
USA C-III.1 p.S1454_L1459dup and p.Q1804∗ (4)
NL2 - p.Q1159Rfs*8 and c.4290+3G>T This study
EST1 - p.V1272M and p.G1808Dfs∗5 This study
EST2 - p.V1272M and p.G1808Dfs∗5 This study
IR - Homozygous p.S951P (4)
IRM - Heterozygous p.S951P (4)
Figure 3. Ultrastructural assessment of the nuclear pore with electron microscopy.
Electron micrographs of patient FIN1/2, AUS and control fibroblasts. Blue arrows indicate nuclear pore complexes and black arrows the nuclear envelope. Scale bars:
2 μm.
ATXN7L3B mRNA expression but not localization is
altered in patient cells
ATXN7L3B protein, encoded by one of the downregulated intron-
less genes (ATXN7L3B), interacts with ENY2 that functions as
an adaptor protein in both the SAGA and TREX-2 complexes
(31). Our qPCR analysis showed that ATXN7L3B mRNA levels
were reduced by 39% on average in patient fibroblasts (Fig. 5C).
Interestingly, in line with this result, we noticed that the GEO
(GSE54481) dataset of GANP siRNAknockdown inhumanHCT116
cells also indicated downregulation of ATXN7L3B (P=1.69e-09,
adj.p.val = 8.43e-06, logFC=−0.935) (9).
To further study whether the ATXN7L3B mRNA localization
was altered in patient cells, we used RNA in situ hybridization
in fibroblasts from nine available patients and three controls
with an ATXN7L3B specific probe. RNA quality of the samples
was validated by using a probe targeting cyclophilin B (PPIB), and
background staining was assessed by a probe targeting bacterial
gene dapB. All samples expressed a high level of the PPIB, and no
signal was detected for dapB. In control cells, ATXN7L3B probe
showed a strong punctate signal across the proximal and distal
regions of the cytoplasm, whereas in patient cells, the cyto-
plasmic signal was reduced (Fig. 6A). Quantitation showed that
the average number of puncta per cell was significantly lower
in patient cell lines compared with control cell lines (P<0.05)
(Fig. 6B). No signs of ATXN7L3B mRNA retention in the nucleus
were noted in patient or control cells.
Although other SAGA or TREX-2 subunits were unaltered in
RNASeq analysis,we additionally validated the expression levels
of ENY2,USP22 andATXN7L3 using qPCR on the full set of patient
lines. In agreement with the RNASeq results, ENY2 and USP22
were not altered; however, ATXN7L3 expression was increased
by 27% on average in patient cells in comparison with controls
(P=0.02) (Supplementary material, Fig. S4).
Discussion
Disruptions in RNA metabolism are increasingly recognized as
causes of a range of neurological phenotypes (32). Owing to the
complexity of mRNA life cycle and the interdependence of its
different steps, it is not surprising that even small changes in
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Figure 4. Differentially expressed genes in patient fibroblasts.
(A) Pearson hierarchical correlation of gene expression of affected individuals’ and control fibroblasts. C indicates control. (B) Volcano plot showing expression
differences and significance for genes. Of the TREX-2/SAGA complex associated genes MCM3AP and ATXN7L3B are indicated in green and non-significant USP22,
ENY2 and ATXN7L3 in grey. (C) Heatmap of expression differences (to gene average) for the enriched genes in REACTOME category ‘neuronal system’. See full list in
Supplementary material Table S2. (D) Gene-set enrichment analysis. See full list in supplementary material Table S3.
the amount or activity of the machinery responsible may have
widespread deleterious effects in neurons. Here we studied a
protein recently associated with human neurological disease,
GANP, which contributes to mRNA maintenance pathways, and
to symptoms of peripheral and central nervous system disease.
Several separate studies have now identified biallelic
MCM3AP mutations as causes of neuropathy with or without
intellectual disability (1,2,3,4,5). The phenotype of the EST
patients in this study was similar to that of the previously
described Finnish patients who carried the same p.Val1272Met
variant combined with a different truncating variant. All
patients from these two families had early disease onset with
upper motor neuron signs, and lost ambulation in adolescence
or early adulthood. The Estonian patients had additionally
progressive encephalopathy starting around ages 11–12 years.
The patient NL2 had a severemotor phenotypewith early central
involvement. These findings increasingly indicate a role for
GANP in central nervous system in addition to the peripheral
nerves.
Because it forms the scaffold of the TREX-2 complex, GANP
has a crucial role inmediating the export ofmRNAs fromnucleus
to cytosol and most likely also influences the upstream steps of
mRNA transcription and processing (7,9). However, GANP func-
tion and regulation in human cells is not fully understood. Our
molecular characterization of patient fibroblasts with various
GANP defects showed that compound heterozygous MCM3AP
variants outside the mRNA binding Sac3 domain led to a dra-
matic decrease of the GANP protein at the nuclear envelope.
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Figure 5. Downregulation of intronless genes in patient fibroblasts.
(A) Distribution of exons across differentially expressed genes. (B) Volcano plot
indicating expression differences for up- and downregulated intronless genes
in log2FC in patient versus control samples and significance as –log10 p-value.
(C) qPCR validations of intronless genes ATXN7L3B, EID1 and TSPYL4 relative to
GAPDH. Each dot represents average of three technical replicates of an affected
(n=8) or control individual (n=4). ∗∗ P< 0.0001. Error bars show mean with SD.
In cells from these individuals, GANPwas nearly undetectable by
immunostaining, whereas fibroblasts from Sac3 variant carriers
had normal GANP levels. Modeling of Sac3 disease variants in
the S. cerevisae Sac3:Thp1:Sem1 complex suggested that the Sac3
variants associated with human disease may generate local
structural changes that could in turn impair binding to RNA
and so could provide a pathogenic mechanism in these cases
when the levels of GANP protein remained near normal. Overall,
our studies indicate that MCM3AP-associated mutations cause
loss of GANP function. The unexpectedly strong depletion of
GANP in the compound heterozygous patients explains why
the associated phenotypes are more severe than those caused
by Sac3 variants. Nevertheless, the phenotypes caused by both
mutation types are quite similar, suggesting that the loss of
mRNA binding function of GANP is a principal mechanism by
which neuronal function is impaired.
Although skin fibroblasts are not the cell type affected in
theMCM3AP-associated disease, detecting the severe GANP loss
in the patient cells prompted us to study whether depletion
of GANP has general effects on mRNA metabolism in fibrob-
lasts. The neuronal disease could result from a molecular defect
that is present in all cell types, but which only manifests in
selected neurons due to profound downstream consequences of
selected transcripts that are highly important in those neuron
types. In line with GANP depletion having an effect, we found
that fibroblasts frommultiple affected individuals with different
pathogenic variants shared similar transcriptional fingerprints.
Higher proportions of differentially expressed geneswere upreg-
ulated than downregulated, suggesting compensatory effects
upon GANP depletion. Unexpectedly, many of the upregulated
genes were involved in neuronal functions. This could sug-
gest that GANP has a specific role in the expression of neu-
ronal transcripts that result in their misregulation even in a
non-neuronal cell type. Future studies using GANP-deficient
human neurons derived from induced pluripotent stem cells
are required to investigate the involvement of these neuronal
transcripts further. Of note, potassium channels within the dif-
ferentially expressed genes may be of interest, as hypokalemic
periodic paralysis was associated with a heterozygous missense
Sac3 variant in one family (6).
GANP has previously been found to have a role in selective
mRNA export, affecting the transport of mRNAs differentially,
with preference on genes that require less processing, that is,
have less introns (9).We studied here the global effect of disease-
associated GANP variants on steady-state mRNA levels, and not
the effect on transport itself. We found no overall indication
of GANP defects having a stronger effect on transcripts with
fewer introns, but interestingly the distribution of intron con-
tent was different between significantly altered upregulated and
downregulated genes, with downregulated genes having fewer
introns. These findings suggest that GANP may have a role in
the regulation of transcription and splicing processes in human
cells in addition to mRNA export. In particular, we observed
that many of the downregulated genes were intronless, whereas
all upregulated genes had introns. Whereas it is known that
intron-containing genes are surveyed by quality control mech-
anisms to ensure that unspliced mRNAs are not exported (17),
the export mechanisms of intronless genes have not been inves-
tigated in great detail. TREX has been suggested to be involved in
export of intronlessmRNAs inHeLa cells (33),NXF1/TAP pathway
in exporting intronless histone H2A mRNA (34) and nuclear
pore basket protein TPR in export of intronless transcripts (35).
ATXN7L3B was one of the downregulated intronless genes in
patients’ cells where RNA in situ hybridization showed a reduc-
tion in its overall amount but no change in mRNA localization
and no evidence for nuclear retention. Therefore, there appears
to be a clear feedback from defect in GANP to steady-statemRNA
levels depending on whether the genes have introns to process.
We speculate that in neurons, this effect on intronless genes
may be rate-limiting for a set of key genes in development and
maintenance of the nervous system. Furthermore, our results
suggest that export of intronless mRNAs may require TREX-2 in
addition to TREX.
In the RNASeq analysis of GANP-deficient patient fibrob-
lasts, ATXN7L3B was the only altered transcript of the TREX-2,
TREX or SAGA complex subunits. ATXN7L3B binds ENY2 (36),
which is a key protein in both the TREX-2 and SAGA complexes
(10,31,36,37). SAGA is a large chromatin modifying coactivator
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Figure 6. ATXN7L3B RNA in situ hybridization shows reduced signal in patient fibroblasts.
(A) Patient and control fibroblasts hybridized with ATXN7L3B target probe (Cy3) and dapi (blue).White square indicates focus area on the other image. Scale bars: 10 μm.
(B) Average of punctae number in cells/line is plotted in the bar graph. P< 0.05. Mean with SD plotted.
complex with modules for the acetylation (HAT) and deubiq-
uitination (DUB) of histones as well as non-histone substrates.
The DUB module removes monoubiquitin from K120 of human
H2B (H2Bub1) in genes and has USP22 as the catalytic subunit
and ATXN7L3 and ENY2 as adaptor proteins for activity and
stability. A recent study found that ATXN7L3B, a cytoplasmic
paralog of ATXN7L3, expressed from a pseudogene, competes
with it for ENY2 binding, thus inhibiting the ability of SAGA
complex to deubiquitinate histones (36). Whereas we found
decreased ATXN7L3B expression in patient cells, qPCR analysis
indicated increased ATXN7L3, supporting a connection between
these two factors. Recent study has interestingly linked the
GANP and SAGA connection to genome stability, by showing
that a functional interaction between human TREX-2 and the
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DUB activity of SAGA is needed to maintain the H2B/HB2Bub1
balance for efficient DNA repair and homologous recombination
(38). These authors showed that, whereas cells lacking ENY2
had increased H2Bub1 levels due to decreased deubiquitination,
GANP-depletion decreased global H2Bub1. Whether the human
disease-associated GANP defects have an effect on SAGA func-
tion requires further studies. Interestingly, ATXN7L3B may well
have relevance for the neurological phenotypes associated with
GANP defects, as two studies have described aberrations affect-
ing the chromosomal region for ATXN7L3B with links to neuro-
logical phenotypes (39,40). In conclusion, our results suggest that
GANP is a regulator of ATXN7L3B expression.
In summary, we describe central nervous system involve-
ment in new affected individuals with MCM3AP variants and
provide a molecular explanation for the genotype/phenotype
correlation through investigation of multiple cell lines from
patients with GANP defects. Our results suggest a novel link
between mRNA export and intron-dependent regulation of gene
expression in human disease.
Materials and Methods
Fibroblast cell culture
Human fibroblast cultures were established from skin punch
biopsies and cultured by standard methods. Briefly, cells were
cultured in 37◦C in 5% CO2 and 95% O2 in DMEM media
(#BE12-614F, Lonza), 10% FBS, 1% penicillin–streptomycin, 1% L-
glutamate and 0.1% uridine. Low-passage fibroblasts of affected
individuals NL1 (female), USA (female), FIN1 (female), FIN2
(male), AUS (female), NL2 (female), EST1 (male) and EST2
(female), IR (female), andNLM referring tomother ofNL1 and IRM
to mother of IR and two to four healthy volunteer controls were
used for the experiments (controls are named per experiment).
The affected individuals or their guardians gave a voluntary
informed consent to participate in the experiments.
Exome and genome sequencing
For EST family, whole genome sequencing and data processing
were performed by the Genomics Platform at the Broad Institute
of MIT and Harvard. PCR-free preparation of sample DNA (350 ng
input at >2 ng/ul) is accomplished using Illumina HiSeq X Ten
v2 chemistry. Libraries are sequenced to a mean target coverage
of >30x. Genome sequencing data were processed through a
pipeline based on Picard, using base quality score recalibration
and local realignment at known indels. The BWA aligner was
used for mapping reads to the human genome build 38. Single
Nucleotide Variants (SNVs) and insertions/deletions (indels) are
jointly called across all samples using Genome Analysis Toolkit
(GATK) HaplotypeCaller package version 3.4. Default filters were
applied to SNV and indel calls using the GATK Variant Quality
Score Recalibration (VQSR) approach.Annotationwas performed
using Variant Effect Predictor (VEP). Lastly, the variant call set
was uploaded to seqr for collaborative analysis between the
Broad Center of Mendelian Genomics and investigator.
For NL2 family, exome sequencing was outsourced to
GenomeScan (Leiden, The Netherlands). In brief, exomes were
captured using the Agilent SureSelectXT Human all Exon v5
library kit (Agilent, Santa Clara, USA) accompanied by Illumina
paired end sequencing on the Hiseq2500 platform (Illumina, San
Diego, USA), generating 2×150 bp paired end reads with at least
80x median coverage. Data analysis was performed at the LDGA
using the in-house sequence analysis pipeline ‘Modular GATK-
Based Variant Calling Pipeline’ (MAGPIE) (LUMC Sequencing
Analysis Support Core, LUMC) based on read alignment using
Burrows-Wheeler Alignment (BWA-MEM) and variant calling
using the Genome Analysis Toolkit (GATK). LOVDplus (Leiden
Genome Technology Center, LUMC, Leiden) was used for
interpretation of variants. Variants were classified according to
the American College of Medical Genetics and Genomics (ACMG)
guidelines.
Fibroblast RNA sequencing and bioinformatics analysis
RNAwas isolated from 90 to 100% confluent 10-cm plates, grown
in culture for 4 days. Technical duplicates were sequenced and
analyzed for all cell lines,whichwere passaged at the same time.
All the fibroblast lines were in early passage stages and grew
at approximately equal pace. Cells were washed with PBS once,
scraped and centrifuged 1000 rcf for 5 min. Pellets were imme-
diately processed for RNA isolation with Nucleospin RNA kit
(#740955.50, Macherey-Nagel) according to the manufacturer’s
instructions including rDNAse treatment. RNA concentrations
were measured with Agilent TapeStation and Nanodrop, RNA
integrity was checked on a gel with Agilent TapeStation and
RIN were≥9.6. RNAmeasurements and mRNA sequencing were
done at Biomedicum Functional Genomics Unit with paired-end
sequencing with Poly A binding beads and NEBNext Ultra Direc-
tional RNA Library Prep and sequenced with Illumina NextSeq
High Output 2 x 75 bp. Target number of reads was 45–50 M,
which was ensured by sequencing with Next Seq Mid Output
flow cell.
The rawdatawere demultiplexedwith adapter removal using
bcl2fastq2 (v2.20.0.422; Illumina). FASTQ-files were filtered with
Trimmomatic (v.0.36; (41)) excluding non-paired, short (<35 bp)
and low quality (phread score<20) reads. The filtered reads
were mapped to the human reference genome (GRCh38) with
STAR (v. 2.5.3; (42)). Expression analysis was carried out in R (R
Development Core Team & Core, 2018). Read counts for genes
were extracted with Rsubreads (v.1.32.4; (43)) excluding dupli-
cates, multimapping reads, chimeric fragments and reads with
low mapping quality (<10). Differential gene expression was
analyzed using DESeq2 (v.1.22.2; (30)), comparing disease status
(control versus patient). The technical replicates were combined,
after confirming that the expression profiles were nearly identi-
cal. Geneswith low read depth (<50 reads in total) were excluded
from the analysis. The results from the expression analysis
along with the raw sequence data were deposited to GEO, under
accession GSE135098.
cDNA synthesis and RT-PCR
Fibroblast total RNA was isolated with Nucleospin RNA kit
(#740955.50, Macherey-Nagel). cDNA was synthesized according
to the manufacturer’s instructions with Maxima First Strand
cDNA Synthesis Kit (#K1671, Thermo Fisher Scientific).
qRT-PCR
Quantitative Real Time PCR for quantification ofMCM3APmRNA
amount, as well as RNA sequencing validations was done with
cDNA isolated as described above. qPCR was run on a CFX96
Touch Real-Time PCR detection system (Bio-Rad) with SYBR
Green qPCR Kit (#F415S, Thermo Fisher Scientific) on a 96-well
plate with gene-specific primers 10 μM and H20. The cycling
protocol was 95◦C for 7 min, then 40 cycles of 95◦C for 10 s and
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60◦C for 30 s. The primers were tested to fit on a standard curve.
Normalization was done with GAPDH as a housekeeping gene.
Technical triplicates were used for all studies. 12.5 ng of cDNA
was used.
Immunocytochemistry, fluorescence microscopy and
confocal microscopy
Fibroblasts were grown in standard cell culture conditions as
described above on cover glasses in 6- or 24-well plates for 4 days,
and media was changed every other day. The confluent cells
were washed three times with PBS, fixed with 4% paraformalde-
hyde for 15 min and washed three times with PBS. Cells were
then permeabilized in 0.2% Triton X-100 in PBS for 15 min in
room temperature. Coverslips were washed three times in PBS-
T (0.1% Tween-20) followed by blocking in 5% BSA/PBS-T (#001-
000-162, Jackson Immuno Research) for 2 h in room temperature
on a shaker. Primary antibody in 5% BSA/PBS-T was incubated
overnight at 4◦C. The following day, coverslips were washed
with PBS-T for 15 min three times, followed by incubation in
secondary antibody in 5% BSA/PBST for 1 h on a shaker. Finally,
the cells were washed three times for 10min and plated on glass
with Vectashield (#H-1200, Vector Laboratories).
Fibroblasts with GANP staining were quantified by manually
counting under a fluorescent microscope (Zeiss). The number
of GANP positive and negative cells was counted in a blinded
manner from triplicate samples, from dapi positive nuclei,
nmean = 112 (first experiment) nmean = 136 (second experiment)
nmean = 90 duplicate samples (third experiment). The groupswere
GANP positive, GANP negative and moderately GANP positive
nuclei. The fibroblasts were imaged with Zeiss LSM880 IndiMo
Axio Observer laser scanning confocal microscope with ZEN
black software with DyLight 594 (GANP) imaged with laser 561
and Dapi imaged with laser 405 using the same exposure time
for all samples. Imaging objective was Plan-Apochromat 63x/1.4
Oil Dic M27, and images were acquired at 8-bit depth and 512 x
512 (experiments B and C) or 1380 x 1380 (experiment A) frame
size. The settings for the 561 laser (excitation 561, emission 659)
were: 1.4% laser power, binning 1 x 1. The results were visualized
with Zen Blue, Image J and Graph Pad Prism Software.
RNA in situ hybridization
RNA in situ hybridization was performed on fixed adherent
fibroblast cells grown on four-chamber slides using RNAscope
Multiplex Fluorescent Reagent Kit Version 2 (#323100, Advanced
Cell Diagnostics) for target detection according to instructions.
Duplicates were analyzed for target probe and single wells for
negative and positive controls per sample. In short, the cells
were fixed in 10% neutral buffered formalin and dehydrated
in increasing concentrations of ethanol (50%, 70% and absolute
ethanol). The cells were stored in absolute ethanol in −20◦C
until performing the RNA in situ hybridization. Next, the cells
were rehydrated in decreasing concentrations of ethanol (70%
and 50%) and washed in PBS. The probes PPIB (positive control,
#313901), dapB (negative control, #310043) and ATXN7L3B (target
probe, #804431) were hybridized for 2 h at 40◦C followed by signal
amplification and developing the HRP channel with TSA Plus
fluorophore Cyanine 3 (1:1500 dilution) (NEL744001KT, Perkin
Elmer) according to the manual. The cells were counterstained
with DAPI and mounted with ProLong Gold Antifade Mountant
(P36930, Invitrogen). The samples were scanned with 3DHIS-
TECH Pannoramic 250 FLASH II digital slide scanner using 40x
objective and extended focus option with seven focus levels.
Punctae number was counted on Pannoramic viewer per cell and
averaged per sample (average 24 cells per sample). Images were
generated using 3DHISTECH Pannoramic 250 FLASH II digital
slide scanner at Genome Biology Unit supported by HiLIFE.
Western blotting
Fibroblasts for protein analysiswere grownon 10-cmpetri dishes
until confluent. The cells were isolated with 1X RIPA (#9806, Cell
Signaling) for 5 min on ice, scraped and centrifuged at 14 000g
for 10 min at 4◦C. Protein concentrations were measured with
Bradford (#500-0006, Bio-Rad) from triplicate samples and with
a standard curve. For SDS-PAGE analysis of affected and control
fibroblasts, 30 μg of proteinwas loaded perwell on a 10%TGX 10-
well 30 μL/well gel (456-1033, Bio-Rad) for 1 h. at 150 V.Molecular
size of bands was detected with protein standard (#161-0374,
Bio-Rad) and proteins loaded together with 4x Laemmli load-
ing buffer (#161-0747, Bio-Rad) in 2-mercaptoethanol (#1610710,
Bio-Rad). Gel was transferred into a nitrocellulose membrane
(#1704158, Bio-Rad) and transferred usingHighMolecularWeight
protocol in Trans-Blot Turbo (Bio-Rad). The blot was washed and
blocked in 5% milk/TBST for 1 h in RT. For immunoblotting anal-
ysis, GANP antibody (1:1000) (#113295, Abcam) was incubated
for 48–72 h in 4◦C in 2.5% milk/BSA in TBS-T. The blot was
washed three times for 5 min in TBS-T. Secondary antibody α-
rabbit (1:5000) in 1% BSA/TBS-T was incubated for 1 h at RT
on a shaker and washed for three times a 10 min in TBS-
T. The blot was visualized with ECL reaction with Pierce ECL
Western Blotting Substrate (#32106, Thermo Fisher). Loading
control GAPDH (#14C10) was incubated overnight in 4◦C and
processed otherwise in the sameway. The images were obtained
with a Chemidoc imager (Bio Rad) and quantified on Image Lab
software (Bio-Rad). The quantification was done using GAPDH
to normalize protein levels of GANP. Results were visualized on
Graph Pad Prism Software.
Antibodies
α-rabbit N-terminal GANP antibody for immunocytochemistry
was (#198173, Abcam), used at a ratio of 1:200. DyLight or Alexa
594 goat-anti-rabbit secondary (#35560, Thermo Fisher; Alexa
fluor) was used to detect GANP at 1:1000. N-terminal antibody
used for western blotting of α-rabbit GANP (#113295, Abcam) was
used at a ratio of 1:1000. Secondary antibody to detect GANP
in immunoblotting was goat-anti-rabbit (#111-035-144, Jackson
Immuno Research), at a ratio of 1:5000.
Molecular modeling
The structure of GANP in the Sac3 region was based on the
crystal structure of this region in the S. cerevisiae TREX-2 complex
(27,28), PDB accession codes 3T5V and 5UBP. This modeling was
justified because of the high sequence homology between the
human and yeast proteins in this region. Images and movies
were generated using the CCP4MG software package.
Transmission electron microscopy
Fibroblast cultures on glass slides were fixed with 2% PFA+2%
glutaraldehyde (Sigma) for 30 min at 4◦C, washed with PBS and
finally with 2% glutaraldehyde O/N at 4◦C. Fixed cells were pre-
pared according to standard protocols for transmission electron
microscopy at the Electron microscopy Unit of the Institute of
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Biotechnology. Images were captured with the Jeol 1400 TEM
microscope at 80 000 V.
Statistics
Unpaired parametric two-tailed t-test was used for qRT-PCR and
RNAScope experiments in which two biological groups were
compared (affected individuals versus controls). Significance
was measured by P<0.05. Statistical tests were performed in
Graph Pad Prism 7.04. Fisher’s exact test was used for analysis of
immunocytochemical staining data. For intron distribution test-
ing Wilcoxon rank sum test with continuity correction (Mann–
Whitney U test) was used. For analysis of GEO siRNA data,
analysis was run in GEO2R browser comparing GANP KD and
control samples, and statistics were reported from the results
table. All measured data points were included in the analysis.
Data availability
RNA-Seq data: Gene Expression Omnibus GSE135098 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135098).
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